Ultreum Capital is a private investment firm that specialises in innovation Life Science.
About Us
Ultreum Capital is a private investment firm that specializes in the innovation Biotechnology and Pharmaceutical sectors in the USA.
We execute unique investments in early stage companies that have demonstrated proof of concept and are at an inflection point of large scale growth. While our core focus is in Life Science, we have diversified our portfolio by investing in the disruptive Technology sector as well.
Ultreum is a financial and strategic investor with a strong network across USA, Europe, Middle East, and Asia. We support our portfolio companies by facilitating strategic alliances and raising of additional capital along with our network of global affiliates.
The companies within our portfolio have reputable founders and management teams along with the foremost strategic investors such as BlackRock, Johnson and Johnson, Citi Ventures, HP, Samsung, and PepsiCo.
Biotech and Pharma Venture Capital
Areas
- Infectious Diseases
- Orphan Indications
- Ophthalmology
- Gene Therapy
- Cell Therapy
- Oncology
Scope
- Vaccines
- Platform Technologies
- Reformulations and Repurposed Drugs
- Novel Therapeutics and Immunotherapies
- Early to late stage clinical trials with human proof of concept
- Drugs with significant improvements over current standard of care
Technology Venture Capital
Areas
- Artificial Intelligence
- Consumer Tech
- Cybersecurity
- Cloud
Scope
- Growth stage companies
- Disruptive and breakthrough technologies
- Technology that resolves current and future complexities
- Companies that will rapidly capture and control the market
Capital Markets
Healthcare
Clinical and commercial stage Life Science companies specialised in novel therapeutics and vaccines.
Technology
Disruptive growth stage companies across Cloud, Artificial Intelligence, Cybersecurity, and Fintech.
Strategic Life Science Initiatives
Ultreum collaborates and syndicates with global market leaders and early stage Life Science companies to create:
- Commercial and licensing alliances
- Research and development partnerships
- New drug development program collaborations
- Manufacturing, supply and distribution joint ventures